日本ケミファの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/04/12 | 1,641 | 1,647 | 1,629 | 1,645 | +4 | +0.2% | 3,900 |
| 2024/04/11 | 1,631 | 1,645 | 1,631 | 1,641 | +10 | +0.6% | 2,400 |
| 2024/04/10 | 1,637 | 1,637 | 1,628 | 1,631 | -6 | -0.4% | 2,300 |
| 2024/04/09 | 1,627 | 1,637 | 1,627 | 1,637 | +6 | +0.4% | 2,100 |
| 2024/04/08 | 1,631 | 1,631 | 1,626 | 1,631 | -1 | -0.1% | 2,000 |
| 2024/04/05 | 1,632 | 1,639 | 1,630 | 1,632 | -29 | -1.7% | 2,300 |
| 2024/04/04 | 1,648 | 1,661 | 1,639 | 1,661 | +26 | +1.6% | 3,200 |
| 2024/04/03 | 1,625 | 1,660 | 1,618 | 1,635 | +5 | +0.3% | 6,000 |
| 2024/04/02 | 1,640 | 1,643 | 1,630 | 1,630 | -19 | -1.2% | 2,700 |
| 2024/04/01 | 1,650 | 1,660 | 1,644 | 1,649 | ±0 | ±0% | 3,200 |
| 2024/03/29 | 1,638 | 1,649 | 1,637 | 1,649 | +1 | +0.1% | 2,600 |
| 2024/03/28 | 1,671 | 1,680 | 1,648 | 1,648 | -52 | -3.1% | 12,900 |
| 2024/03/27 | 1,700 | 1,700 | 1,682 | 1,700 | ±0 | ±0% | 8,800 |
| 2024/03/26 | 1,698 | 1,700 | 1,683 | 1,700 | +18 | +1.1% | 3,500 |
| 2024/03/25 | 1,687 | 1,697 | 1,682 | 1,682 | -5 | -0.3% | 8,300 |
| 2024/03/22 | 1,689 | 1,695 | 1,687 | 1,687 | ±0 | ±0% | 4,400 |
| 2024/03/21 | 1,667 | 1,696 | 1,667 | 1,687 | +25 | +1.5% | 5,300 |
| 2024/03/19 | 1,634 | 1,666 | 1,634 | 1,662 | +28 | +1.7% | 7,400 |
| 2024/03/18 | 1,640 | 1,647 | 1,634 | 1,634 | +4 | +0.2% | 4,100 |
| 2024/03/15 | 1,630 | 1,630 | 1,626 | 1,630 | -4 | -0.2% | 2,300 |
| 2024/03/14 | 1,620 | 1,634 | 1,620 | 1,634 | -2 | -0.1% | 2,100 |
| 2024/03/13 | 1,631 | 1,639 | 1,616 | 1,636 | +7 | +0.4% | 4,400 |
| 2024/03/12 | 1,617 | 1,629 | 1,617 | 1,629 | +13 | +0.8% | 1,100 |
| 2024/03/11 | 1,617 | 1,631 | 1,615 | 1,616 | -1 | -0.1% | 7,100 |
| 2024/03/08 | 1,630 | 1,630 | 1,613 | 1,617 | -17 | -1% | 4,700 |
| 2024/03/07 | 1,635 | 1,640 | 1,617 | 1,634 | -2 | -0.1% | 8,000 |
| 2024/03/06 | 1,614 | 1,636 | 1,614 | 1,636 | +13 | +0.8% | 3,700 |
| 2024/03/05 | 1,615 | 1,637 | 1,615 | 1,623 | +6 | +0.4% | 2,600 |
| 2024/03/04 | 1,615 | 1,627 | 1,607 | 1,617 | +6 | +0.4% | 5,100 |
| 2024/03/01 | 1,603 | 1,620 | 1,603 | 1,611 | -9 | -0.6% | 4,100 |
| 2024/02/29 | 1,624 | 1,629 | 1,616 | 1,620 | -4 | -0.2% | 3,400 |
| 2024/02/28 | 1,610 | 1,638 | 1,610 | 1,624 | +2 | +0.1% | 6,700 |
| 2024/02/27 | 1,610 | 1,641 | 1,610 | 1,622 | +8 | +0.5% | 4,500 |
| 2024/02/26 | 1,638 | 1,638 | 1,614 | 1,614 | -4 | -0.2% | 4,300 |
| 2024/02/22 | 1,626 | 1,632 | 1,618 | 1,618 | -8 | -0.5% | 3,800 |
| 2024/02/21 | 1,617 | 1,645 | 1,617 | 1,626 | ±0 | ±0% | 3,500 |
| 2024/02/20 | 1,622 | 1,636 | 1,617 | 1,626 | +11 | +0.7% | 2,400 |
| 2024/02/19 | 1,606 | 1,619 | 1,600 | 1,615 | -1 | -0.1% | 2,900 |
| 2024/02/16 | 1,606 | 1,623 | 1,593 | 1,616 | +10 | +0.6% | 3,500 |
| 2024/02/15 | 1,610 | 1,617 | 1,595 | 1,606 | -2 | -0.1% | 8,700 |
| 2024/02/14 | 1,609 | 1,617 | 1,602 | 1,608 | -1 | -0.1% | 5,700 |
| 2024/02/13 | 1,626 | 1,626 | 1,606 | 1,609 | -2 | -0.1% | 5,200 |
| 2024/02/09 | 1,611 | 1,629 | 1,606 | 1,611 | +1 | +0.1% | 4,600 |
| 2024/02/08 | 1,627 | 1,627 | 1,610 | 1,610 | +5 | +0.3% | 3,300 |
| 2024/02/07 | 1,623 | 1,623 | 1,601 | 1,605 | -18 | -1.1% | 4,100 |
| 2024/02/06 | 1,614 | 1,629 | 1,606 | 1,623 | +25 | +1.6% | 3,400 |
| 2024/02/05 | 1,619 | 1,622 | 1,598 | 1,598 | -7 | -0.4% | 15,700 |
| 2024/02/02 | 1,598 | 1,613 | 1,597 | 1,605 | +7 | +0.4% | 4,100 |
| 2024/02/01 | 1,610 | 1,614 | 1,597 | 1,598 | -3 | -0.2% | 13,800 |
| 2024/01/31 | 1,592 | 1,612 | 1,592 | 1,601 | +12 | +0.8% | 5,100 |
151～
200
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 日ケミファ | 151,400円 | +2.5% | - | 3.30% | 91.04倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ＯＴＳ | 3,000円 | +63.9% | - | 0.00% | - | 8.80倍 |
|
がん治療ワクチン創薬ベンチャー。大手製薬と開発提携。東大医科研発。会社計画は非開示 |
| ノイルイミューン | 17,500円 | -97.8% | - | 0.00% | - | 1.52倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ＶＩＳ | 90,100円 | +87.8% | +265.7% | 0.00% | 54.11倍 | 2.48倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
該当銘柄がありません
チャート関連のコラム
